Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 299

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 299
---
 pre money valuation of $5,150.

On January 3, 2024, the Company extended
the due date of the 2020 Notes until April 30, 2024 and, subsequently, on April 26, 2024, further extended the due date until May 27,
2024, and in March 2025 further extended to August 31, 2025. Regarding additional term extension, see also Note 9.

| b. | In October 2024, the Company                                                                           
 entered into an addendum to the 2020 CLAs (the “October 2024 CLA Addendum”) pursuant                   
 to which the Company will issue additional notes up to an additional aggregate amount of $450 to       
 certain lenders (the “Participating Lenders”). Pursuant to the October 2024 CLA Addendum,              
 the 2020 Notes held by the non-participating lenders will bear interest at 8% per annum until maturity 
 commencing as of July 1, 2024, and the 2020 Notes held by the Participating Lenders commencing on      
 March 31, 2025. In addition, pursuant to the October 2024 CLA Addendum, upon the earlier of March      
 31, 2025 or occurrence of an IPO, the 2020 Notes principal and accrued interest will be automatically  
 converted into 609,888 Ordinary Shares based on a pre money valuation of $5,150. In addition, upon     
 conversion of the CLAs to Ordinary Shares the Company will issue additional 553,640 Ordinary Shares    
 to the Participating Lenders which presents the additional amount provided by Participating Lenders,   
 the applicable accrued interest and the amount of $340 as a risk premium. On March 31, 2025, the       
 Company and the lenders signed an amendment to the loan agreement to extend the maturity date until    
 the earlier of August 31, 2025 or consummation of an IPO. As of June 30, 2025, the Company received    
 proceeds of $450 proceeds from the issuance of the additional 2020 Notes.                              |

<div align='center'>F-42</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 5:- | CONVERTIBLE NOTES (Cont.) |

The Company estimates